Some works demonstrated that a decrease in CCR2, which further identifies and purifies Ly6hi inflammatory monocytes, predicted a better outcome in ALS patients, as the inflammatory monocyte activation seemed to be more destructive than protective and accelerated the disease progression, thus resulting in a worse prognosis [49]. The gene discussed is CCR2; the disease is amyotrophic lateral sclerosis.